Clinical Trial: Multi-center Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Share this article:
Clinical Trial: Multi-center Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Sponsor and Collaborators

Chronic Lymphocytic Leukemia Research Consortium
Celgene Corporation

Contact
Contact: Mary Carpenter, CRC
858-822-5635
mcarpenter@ucsd.edu

Contact: Danelle F James, MD
858-822-7894
dfjames@ucsd.edu

Principal Investigator
Study Director: Thomas J Kipps, MD, PhD Director of the CLL Research Consortium and University of California San Diego

Principal Investigator: Danelle F James, MD, MAS CLL Research Consortium and University of California San Diego

ClinicalTrials.gov Identifier
NCT01199575
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs